Press Releases

SAN ANTONIO, TEXAS-December 21, 2007-Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices held a reception at La Villita Arts Village to honor leadership and program participants of the 30th annual San Antonio Breast Cancer Symposium (SABCS).

The SABCS provided state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease to an international audience of academic and private physicians and researchers. Last year the attendees numbered over 9000 and represented 83 countries.

“As one out of every two deaths in women in the U.S. is due to breast cancer, Seno is excited to be part of the SABCS community as we continue in making advancements in conquering cancer”, said Janet Campbell, Seno Medical CEO. “Seno is honored to host a number of distinguished guests and physicians from across the world during the symposium”.

As part of the SABCS program, Seno presented two poster sessions on its patented opto-acoustic technology: “Initial Clinical Evaluation of Laser Opto-acoustic Imaging System for Diagnostic Imaging of Breast Cancer” and “Molecular Imaging in the Mouse Model of Breast Cancer based on Optical Illumination & Ultrasonic Detection”

During the conference, Seno announced the introduction of its Imagio™ research device, a new platform technology using opto-acoustics for small animal functional imaging. Seno’s break through technology was recognized by the State of Texas in August when the company received a $2 million investment by the Texas Emerging Technology Fund.

At Seno’s reception, guests had the pleasure of listening to a number of distinguished speakers. Speakers included Dr. Robert Kramer, founding member of the Susan G. Komen Advisory Board and a member of the Seno Scientific Advisory Committee as well as State Representative Joe Straus who represents the San Antonio community in the Texas Legislature.

Representative Straus said, “Seno’s breakthrough technology promises breast cancer patients will be able to receive better diagnosis and treatment. The State of Texas is pleased to be its partner.”

SAN ANTONIO, TX September 7, 2007 – Seno Medical Instruments, Inc. will announce the introduction of a new platform technology using opto-acoustics for small animal functional imaging at the Joint Molecular Imaging Conference in Providence, Rhode Island September 8-9.

The Joint Molecular Imaging Conference unites medical professionals and scientists with state of the art technology. Scientists and researchers from around the world will have the opportunity to learn about the Imagio™ research device that uses Seno’s patented laser opto-acoustic imaging technology.

Janet Campbell, CEO of Seno, recently announced a $2 (M) investment by the State of Texas’ Emerging Technology Fund.

“Our opto-acoustic technology will be presented for the first time as a commercial product as the Imagio™ research device. I am pleased that Seno has the opportunity to introduce this technology to such a distinguished group of researchers. Pharmaceutical and biotechnology companies will also be able to utilize Imagio™ for the acceleration of cancer research and drug discovery.” said Campbell.

Imagio™ technology produces real-time color images which distinguish between benign and malignant growths for all solid tumors and is expected to be a breakthrough for cancer detection. The research device produces detailed, full-scope images of small laboratory animals, such as nude mice. The image contrast is related to both blood volume and oxygenation status, allowing lesions to be diagnosed immediately. The new technology provides functional imaging information for cancer researchers, as well as the potential for cancer screening, diagnosis, and therapeutic treatments more humane than existing technologies.

In addition to the September 9 launch of the Imagio™ research device, to honor Conference participants Seno will also sponsor Waterfire Providence, an award winning fire sculpture exhibit and performance spanning three rivers that serves as a moving symbol of Providence’s renaissance. The event is recognized as one of “America’s 100 Best” by Reader’s Digest.

SAN ANTONIO, TEXAS — August 21, 2007 – Seno Medical Instruments, Inc., a company engaged in the development of medical devices announced a $2 million dollar award from the Texas Emerging Technology Fund (TETF). This funding will allow the company to further develop its life saving technology for cancer imaging and detection and move it closer to the global marketplace.

Texas Secretary of State Phil Wilson and Seno Medical Instruments, Inc. CEO Janet Campbell announced the Fund’s investment during a joint press conference at the world renowned Cancer Therapy and Research Center in San Antonio. The patented functional imaging technology will be commercialized to produce real-time color images which differentiate benign and malignant tumors, for all solid tumors, such as in breast cancer. Seno’s intent is to provide the most advanced high quality products for cancer screening, diagnosis and therapeutic treatment that are more humane than existing technologies.

“I am pleased that the state of Texas and its elected leadership recognize and support Seno’s technology, and our effort to create better tools for the detection and treatment of breast cancer. On behalf of my management team, we are grateful for the support we’ve received from our investors and organizations, not only in our hometown of San Antonio, but across Texas and the nation,” said Campbell.

The TETF is a $200 million program created by the Texas Legislature in 2005. A 17-member advisory committee of high-tech leaders, entrepreneurs and research experts reviews potential TETF projects and recommends funding for projects to the Governor, Lieutenant Governor and Speaker of the House. To date, the TETF has allocated $94.1 million in grant funds to Texas companies and universities across the state.

“Technological innovation is the lifeblood of today’s economy,” said Texas Governor Rick Perry. “Texas is making an important investment, literally, in the foundation of our future. By supporting advancing technology projects, such as breast cancer diagnostic devices, we are making a difference in a wide variety of products and services that enhance the quality of lives here today, and in the future.”
Seno Medical has selected the Cancer Therapy and Research Center and the University of Texas Health Science Center at San Antonio to conduct initial clinical studies.

SAN ANTONIO, TEXAS—July 13, 2007—Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices announces the appointment of Lester Crawford, Ph.D., D.V.M. to its Scientific Advisory Committee. Dr. Crawford, widely known for his experience as Deputy Commissioner and Commissioner at the Food and Drug Administration between 2002 and 2005, joins a prestigious group of professionals dedicated to the early detection of cancer.

Seno Medical Instruments, Inc. was formed in 2005 to commercialize a new modality in cancer screening and diagnosis: laser opto-acoustic imaging. To further the development of this potentially life-saving technology, the company is assembling a team of experts in the field of breast cancer detection, product application and protocol design. Dr. Crawford joins Robert L. Kramer, M.D., founding member of the Susan G. Komen Advisory Board and Charles Coltman, M.D., President Emeritus of San Antonio’s Cancer Therapy and Research Center on the committee. Also on Seno Medical’s Scientific Advisory Committee is John W. Holaday, Ph.D., formerly listed among the 500 most cited scientists in the world by the Science Citation Index.

“We are delighted that Dr. Crawford has agreed to join our Scientific Advisory Committee. As a recognized leader of a national organization such as the FDA, we are confident he will bring a wealth of knowledge and experience to the committee and to the company,” said Janet Campbell, Seno Medical CEO.

Dr. Crawford has played major roles in mandatory nutrition labeling, the formation of the World Trade Organization and the control of chemical and microbiological contaminants of food. He has been an advisor to the World Health Organization of the United Nations for much of his career. Previously Chair of Department of Physiology-Pharmacology at the University of Georgia, Dr. Crawford has also been Administrator of the Food Safety and Inspection Service (USDA) and Director of the Center for Food and Nutrition Policy from 1997 to 2002, first at Georgetown University and at Virginia Tech, where it moved in 2001. He is a member of the National Academy of Sciences Institute of Medicine, a Fellow of the Royal Society of Medicine (UK) and a Fellow of the International Society of Food Science and Technology.

SAN ANTONIO, TEXAS—June 12, 2007—Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices announces the selection of John Holaday, PhD to its Scientific Advisory Committee. Dr. Holaday, formerly listed among the 500 most cited scientists in the world by the Science Citation Index, will be instrumental in Seno Medical’s efforts to bring its patented breast cancer diagnostic technology to the global marketplace.

Seno Medical Instruments, Inc. was formed in 2005 to commercialize a new modality in cancer screening and diagnosis: opto-acoustic imaging. To further the development of this potentially life-saving technology, the corporation is assembling a team of experts in the field of breast cancer detection, product application and protocol design.

“I am excited and honored that Dr. Holaday has decided to join our team,” said Janet Campbell, Seno Medical CEO. “Dr. Holaday brings a depth of knowledge in patents, strategic partnering and running successful medical companies. His expertise in science and the medical field will be invaluable to us.”

Dr. Holaday understands that despite the advances in treating breast cancer, the best way to manage the disease and to save lives is early detection. “Seno’s opto-acoustic technology creates a new diagnosis window. The ability to identify malignant tissues from the non-malignant based on differences in metabolic demand represents a breakthrough technology for the diagnosis of breast cancer with potential applicability to other forms of cancer,” said Dr. Holaday.

Dr. Holaday is currently CEO of QRxPharma, a newly listed specialty pharmaceutical company specializing in pain and CNS diseases (QRX, ASX). Dr. Holaday, a veteran life-science entrepreneur, built five public and private biopharmaceutical companies over the past 19 years and raised more than $360M in capital. As Chairman of the Maryland Bioscience Alliance (2000–2004), Dr. Holaday oversaw the largest biotechnology membership-based organization in the State. Dr. Holaday founded EntreMed, (ENMD, NASDAQ) in 1992 and served as its Chairman, President and CEO until his retirement in 2003 and was the co-founder, director, Scientific Director and SVP of Medicis Pharmaceutical Corporation (MRX, NYSE). He was the founder and Chief of the Neuropharmacology Branch at the Walter Reed Army Institute of Research for 21 years. Dr. Holaday is a graduate of the University of California, San Francisco School of Medicine with a PhD in neuropharmacology.

Dr. Holaday has received numerous honors and awards, including induction into Ernst and Young’s Entrepreneur of the Year 2006 Hall of Fame. He holds over 30 U.S. and foreign patents, has published more than 200 scientific articles and reviews, and edited five books.

SAN ANTONIO, TEXAS—May 29, 2007—Seno Medical Instruments, Inc., a San Antonio medical device company, announces its participation in the In3 Medical Device Summit taking place June 3–5. Seno Medical Instruments CEO, Janet Campbell, will present the company’s patented laser opto-acoustic medical imaging technology to attendees. Attendees will include some of the biggest dealmakers in the medical device industry, including members of the healthcare investment community.

Investors and fellow medical device executives will hear about Seno’s platform technology, which combines light and sound to produce high contrast images for cancer detection and treatment. This technology has a multitude of potential cancer applications which include breast, ovarian, prostate, colorectal, bladder and melanoma cancers. This innovative platform technology also has potential non-cancer applications in the areas of cardiovascular, inflammatory disease and stroke.

“We are excited to present our technology at this summit, known as the largest strategic partnership and investment meeting for medical technology executives. This summit is the most important venue of its kind for previewing cutting-edge emerging medical technology companies,” said Campbell, one of the first female CEO’s in the breast cancer imaging industry.

Seno’s initial imaging device for cancer researchers is expected to be released in the first quarter of 2008, with its breast cancer diagnostic to follow. The first clinical applications, breast cancer diagnosis and screening, will target a market estimated to be $5.9B (North America only).